Azitra Issued U.S. Patent No. 11,850,267 Titled "Methods And Compositions For Treating Skin Disease With Recombinant Microorganisms"
Portfolio Pulse from Benzinga Newsdesk
Azitra, Inc. has been granted U.S. Patent No. 11,850,267 for a filaggrin-secreting strain of Staphylococcus epidermidis to treat ichthyosis vulgaris, a condition with no FDA-approved treatment affecting 1.3 million people in the U.S. This patent expands Azitra's IP for its precision dermatology platform, which includes metagenomics and engineered skin bacteria. The company now has 3 granted U.S. patents and several pending applications.
January 16, 2024 | 2:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Azitra's newly issued patent for a skin disease treatment strengthens its IP and could enhance its market position in precision dermatology.
The issuance of a new patent typically provides a company with a competitive advantage and can lead to positive investor sentiment. Given that ichthyosis vulgaris has no FDA-approved treatments, this patent could be particularly significant for Azitra, potentially leading to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100